Maintenance or non-maintenance therapy in the treatment of advanced non-small cell lung cancer: That is the question

Cancer Treatment Reviews

Volumn 36, Issue SUPPL. 3, 2010, Pages

  Galetta, D ^a   Rossi, A ^b   Pisconti, S ^c   Millaku, A ^d   Colucci, G ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b S G MOSCATI HOSPITAL   (Italy)

^c SG Moscati Hospital   (Italy)

^d UNIVERSITY CLINICAL CENTER OF KOSOVO   (Serbia)

Author keywords

Chemotherapy; Erlotinib; Maintenance therapy; NSCLC; Pemetrexed; Targeted therapy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; PACLITAXEL; PEMETREXED; PLACEBO;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; PROGRESSION FREE SURVIVAL; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MOLECULAR TARGETED THERAPY; PROGNOSIS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78649721508     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/S0305-7372(10)70017-7     Document Type: Article

References (20)

1. Parkin DM, Bray F, Ferlay J, Pisani P Global statistics cancer, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End Results database. J Clin Oncol 2006, 24:4539-4544.
3. Azzoli CG, Baker S, Temin S, et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
4. Gridelli C, Maione P, Rossi A, et al. Potential treatment options after first-line chemotherapy for advanced non small cell lung cancer: maintenance treatment or early second-line?. Oncologist 2009, 14:137-147.
5. Shih C, Chen VJ, Gossetti LS, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate requiring enzymes. Cancer Res 1997, 57:1116-1123.
6. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthetase. Cancer 2006, 107:1589-1596.
7. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: A review of two phase III studies. Oncologist 2009, 14:253-263.
8. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
9. Paz-Ares LG, Altug S, Vaury AT, Jaime JC, Russo F, Visseren-Grul C Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer. BMC Cancer 2010, 10:85.
10. Alimta approval as maintenance treatment for nonsquamous NSCLC (accessed on May 30, 2010). http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/021462s018,021462s021,021462s022ltr.pdf.
11. Alimta approval as maintenance treatment for nonsquamous NSCLC (accessed on May 30, 2010). http://www.ema.europa.eu/pdfs/human/opinion/Alimta_33182709en.pdf.
12. Rossi A, Galetta D, Gridelli C Biological prognostic and predictive factors in lung cancer. Oncology 2009, 77(Suppl 1):90-96.
13. John T, Liu G, Tsao MS Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene 2009, 28(Suppl. 1):S14-S23.
14. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521-529.
15. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002, 62:4645-4655.
16. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000, 6:3739-3747.
17. Kabbinavar FF, Miller VA, Johnson BE, et al. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2010, 28(15S):544s. (Abst 7526).
18. Johnson B, Miller V, Amler L, et al. Biomarker evaluation in the randomized, double-blind, placebo-controlled, Phase IIIb ATLAS Trial, comparing bevacizumab (B) therapy with or without erlotinib (E), after completion of chemotherapy with B for the treatment of locally-advance. EJC Suppl 2009, 7:5. [abstract 8LBA].
19. Erlotinib approval as maintenance treatment for nonsquamous NSCLC (accessed on May 30, 2010). http://www.ema.europa.eu/pdfs/human/opinion/TarcevaII_8608010en.pdf.
20. Erlotinib approval as maintenance treatment for nonsquamous NSCLC (accessed on May 30, 2010). http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf.